Switch theme
Sign up to access all valuation multiples
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in Research, development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
1991
n/a
LTM Revenue $404M
LTM EBITDA $131M
$11.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wantai BioPharm has a last 12-month revenue of $404M and a last 12-month EBITDA of $131M.
In the most recent fiscal year, Wantai BioPharm achieved revenue of $309M and an EBITDA of $51.9M.
Wantai BioPharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wantai BioPharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $759M | $309M | XXX | XXX | XXX |
| Gross Profit | $1.4B | $650M | XXX | XXX | XXX |
| Gross Margin | 182% | 210% | XXX | XXX | XXX |
| EBITDA | $225M | $51.9M | XXX | XXX | XXX |
| EBITDA Margin | 30% | 17% | XXX | XXX | XXX |
| Net Profit | $653M | $172M | XXX | XXX | XXX |
| Net Margin | 86% | 56% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Wantai BioPharm's stock price is CNY 67 (or $9).
Wantai BioPharm has current market cap of CNY 85.2B (or $11.7B), and EV of CNY 80.6B (or $11.1B).
See Wantai BioPharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.1B | $11.7B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Wantai BioPharm has market cap of $11.7B and EV of $11.1B.
Wantai BioPharm's trades at 27.5x LTM EV/Revenue multiple, and 85.0x LTM EBITDA.
Analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Wantai BioPharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $11.1B | XXX | XXX | XXX |
| EV/Revenue | 35.9x | XXX | XXX | XXX |
| EV/EBITDA | 214.2x | XXX | XXX | XXX |
| P/E | 801.6x | XXX | XXX | XXX |
| P/E/Growth | 2.7x | XXX | XXX | XXX |
| EV/FCF | -151.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpWantai BioPharm's NTM/LTM revenue growth is 43%
Wantai BioPharm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Wantai BioPharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Wantai BioPharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -59% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -77% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 60% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 39% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wantai BioPharm acquired XXX companies to date.
Last acquisition by Wantai BioPharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Wantai BioPharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Wantai BioPharm founded? | Wantai BioPharm was founded in 1991. |
| Where is Wantai BioPharm headquartered? | Wantai BioPharm is headquartered in China. |
| Is Wantai BioPharm publicy listed? | Yes, Wantai BioPharm is a public company listed on SHG. |
| What is the stock symbol of Wantai BioPharm? | Wantai BioPharm trades under 603392 ticker. |
| When did Wantai BioPharm go public? | Wantai BioPharm went public in 2020. |
| Who are competitors of Wantai BioPharm? | Similar companies to Wantai BioPharm include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Wantai BioPharm? | Wantai BioPharm's current market cap is $11.7B |
| What is the current revenue of Wantai BioPharm? | Wantai BioPharm's last 12-month revenue is $404M. |
| What is the current EBITDA of Wantai BioPharm? | Wantai BioPharm's last 12-month EBITDA is $131M. |
| What is the current EV/Revenue multiple of Wantai BioPharm? | Current revenue multiple of Wantai BioPharm is 27.5x. |
| What is the current EV/EBITDA multiple of Wantai BioPharm? | Current EBITDA multiple of Wantai BioPharm is 85.0x. |
| What is the current revenue growth of Wantai BioPharm? | Wantai BioPharm revenue growth between 2023 and 2024 was -59%. |
| Is Wantai BioPharm profitable? | Yes, Wantai BioPharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
